ANTEROGEN
ANTEROGEN / CELL THERAPY
From cell potential
to tissue recovery
Anterogen researches and develops therapeutics for rare, intractable, and degenerative diseases using an adipose-derived mesenchymal stem cell platform.
2026.04ALLOSTEM SHEET · MHLW Marketing ApprovalJapan Approval Info ↗- 2000Anterogen Founded
- 2012Cupistem Approved
- 2016Listed on KOSDAQ
- 2026ALLOSTEM SHEET Approved in Japan
01NOW · ALLOSTEM SHEET
Cell sheet technology
has reached the approval stage
AlloStem Sheet is an allogeneic adipose-derived mesenchymal stem cell-based tissue-engineered product cultured on a biocompatible scaffold. It received marketing approval from the Japanese Ministry of Health, Labour and Welfare in April 2026.
- PRODUCTALLOSTEM SHEETAPPROVED
- MODALITYAllogeneic MSC · ScaffoldCELL SHEET
- TERRITORYJapan2026.04
02SCIENCE
From cells to therapeutics
Anterogen develops cell therapies and tissue-engineered products based on adipose-derived mesenchymal stem cells.
Explore Research Platform↗Adipose Tissue
Research begins with adipose tissue from the patient or a donor.
Mesenchymal Stem Cells
Cells are isolated from adipose tissue, and their characteristics and quality are verified.
Therapeutics · Cell Sheets
Developed into autologous and allogeneic cell therapies and scaffold-based sheet formulations.
Clinical Trials · Regulatory Affairs
Safety and efficacy are evaluated, and manufacturing processes and regulatory documents are established.
03PIPELINE